Jason Broderick


Promising Clinical Activity Showcased With Olaparib Plus Bipolar Androgen Therapy in Prostate Cancer

September 17th 2021

Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.

TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS

June 8th 2021

The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer

June 8th 2021

Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

June 7th 2021

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC

February 11th 2021

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

May 18th 2020

The FDA has approved single-agent atezolizumab as a frontline treatment for patients with advanced non–small cell lung cancer with high PD-L1 expression.

Alvocidib Trial Launches in MDS

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

May 13th 2020

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

March 12th 2020

The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.

Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial

March 12th 2020

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL

March 12th 2020

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Cirmtuzumab/Ibrutinib Combo Active in Mantle Cell Lymphoma

March 12th 2020

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Zanubrutinib Highly Active in Non-Hodgkin Lymphoma

December 10th 2017

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10th 2017

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

FDA Approval Sought for Frontline Cabozantinib in RCC

August 16th 2017

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.